As part of our Liquid Biopsy development pipeline, we are identifying biomarkers and developing algorithms that can change the way liver cancer is detected and managed. The first paper for our liver cancer early detection liquid biopsy test is out, and can be found here. From the abstract: “… Combining our signature of 38 DNA

Another important step in the development of HepatoPredict and an occasion for celebration: HepatoPredict is now a registered medical device under the DIRECTIVE 98/79/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 October 1998 on in vitro diagnostic medical devices.

Our collaborator from the Cento Hospital Universitário de Lisboa Central (Hospital Curry Cabral) presented an oral communication and discussed our work on predicting relapse after liver transplantation to treat hepatocellular carcinoma at the 28th anual meeting of the European Surgical Association. Lots of discussion and interest.

If you are attending the annual meeting of the International Liver Transplantation Society, come hear about HepatoPredict on Saturday morning, Room 1 – Joana Vaz, PhD, our CSO and co-founder, will present the first batch of clinical validation results.

It is with great joy that we announce that Prof. Marina Berenguer joined Ophiomics’ advisory board.  (From ILTS site) Prof. Marina Berenguer is a Consultant Hepatologist at La Fe University Hospital, Valencia, (Spain). She trained in medicine at the University of Valencia, before completing a fellowship at the VA Medical Center / University of California

Ophiomics (PT) and Biocartis (BE) announce today that they have entered into a collaboration regarding HepatoPredict™, a prognostic test for liver cancer. HepatoPredict™ will be launched as a CE-marked IVD manual kit in Q1 2022. The partnership will initially focus on Biocartis’ commercialization of the manual kit in Europe. In a next stage, depending on

On the last days of 2021 Ophiomics launched the fabrication of its first “production-scale” lot of the HepatoPredict  kit, already in preparation for its anticipated commercial development in Q1 2022, and is now a registered manufacturer of medical devices. It seems impossible that 6 months ago we were still entertaining a different business model, where

Jose Leal presented HepatoPredict at the ESSO 40, in the session Future Oncology, where he had the opportunity to discuss HepatoPredict and its validation roadmap with experts from different institutions.

It is with great joy that we announce that Prof. Christophe Duvoux joined Ophiomics’ advisory board.  (From the ILTS site:) Christophe Duvoux is full Professor of Hepatology and Transplant Hepatogist. He is head of the Medical Liver Transplantation Program at Henri Mondor Hospital-Paris Est University. He has been chairing ELITA (European Liver & Intestine Transplantation